Nurulamin M Noor
A5039515441- Inflammatory Bowel Disease
- Microscopic Colitis
- Health Systems, Economic Evaluations, Quality of Life
- Eosinophilic Esophagitis
- Biosimilars and Bioanalytical Methods
- Statistical Methods in Clinical Trials
- Autoimmune and Inflammatory Disorders
- Diagnosis and treatment of tuberculosis
- Helicobacter pylori-related gastroenterology studies
- Advanced Causal Inference Techniques
- Immunodeficiency and Autoimmune Disorders
- Ethics in Clinical Research
- Colorectal Cancer Screening and Detection
- Child Nutrition and Water Access
- Autoimmune and Inflammatory Disorders Research
- Gastrointestinal disorders and treatments
- Primary Care and Health Outcomes
- Gastric Cancer Management and Outcomes
- Gastrointestinal motility and disorders
- T-cell and B-cell Immunology
- Celiac Disease Research and Management
- Multiple and Secondary Primary Cancers
- COVID-19 and healthcare impacts
- Nutrition and Health in Aging
- Cancer Immunotherapy and Biomarkers
Cambridge University Hospitals NHS Foundation Trust
2018-2025
University of Cambridge
2015-2025
MRC Clinical Trials Unit at UCL
2020-2025
University College London
2019-2025
Medical Research Council
2019-2025
Addenbrooke's Hospital
2016-2025
Cambridge School
2019-2025
Khoo Teck Puat Hospital
2025
Copenhagen University Hospital
2024
Hvidovre Hospital
2024
This is the second of a series two articles reporting European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on management adult patients with ulcerative colitis [UC]. The first article focused medical management, present addresses treatment acute severe [ASUC] surgical medically refractory UC patients, including preoperative optimisation, strategies, technical issues. provides advice for variety common clinical conditions. Together, represent an update recommendations ECCO UC.
We have previously described a prognostic transcriptional signature in CD8 T cells that separates patients with IBD into two phenotypically distinct subgroups, termed IBD1 and IBD2. Here we sought to develop blood-based test could identify these subgroups without cell separation, thus be suitable for clinical use Crohn's disease (CD) ulcerative colitis (UC).
BackgroundManagement strategies and clinical outcomes vary substantially in patients newly diagnosed with Crohn's disease. We evaluated the use of a putative prognostic biomarker to guide therapy by assessing randomised either top-down (ie, early combined immunosuppression infliximab immunomodulator) or accelerated step-up (conventional) treatment strategies.MethodsPROFILE (PRedicting Outcomes For disease using moLecular biomarker) was multicentre, open-label, biomarker-stratified,...
Abstract This article is the second in a series of two publications on European Crohn’s and Colitis Organisation [ECCO] evidence-based consensus management disease. The first covers medical management; present addresses surgical management, including preoperative aspects drug before surgery. It also provides technical advice for variety common clinical situations. Both articles together represent recommendations ECCO disease an update prior Guidelines.
In inflammatory bowel disease [IBD], mucosal healing is a major therapeutic target and reliable predictor of clinical course. However, endoscopic not synonymous with histological healing, the additional benefits including remission as are unclear. Crohn´s [CD], there few studies highlighting value target. Histological activity can persist in CD patients who remission, absence may be associated lower relapse rates. Therefore, standardisation procedures to evaluate desirable. Topics that would...
The course of Crohn's disease (CD) varies substantially between individuals, but reliable prognostic markers do not exist. This hinders management because patients with aggressive are undertreated by conventional 'step-up' therapy (in which treatment is gradually escalated in response to refractory or relapsing disease) while those more indolent would be exposed unnecessary treatment-related toxicity if a 'top-down' approach was indiscriminately used. Predicting outcomes for using molecular...
Abstract Despite the introduction of biological therapies, an ileocolonic resection is often required in patients with Crohn’s disease [CD]. Unfortunately, surgery not curative, as many will develop postoperative recurrence [POR], eventually leading to further bowel damage and a decreased quality life. The 8th Scientific Workshop ECCO reviewed available scientific data on both prevention treatment POR CD undergoing resection, dealing conventional well non-medical interventions, including...
Abstract There are now a growing number of licensed biological therapies for patients with Crohn’s disease. However, there can be significant costs associated long-term maintenance treatment, as well some concerns about potential side-effects. As result, has been increasing interest in elective treatment discontinuation selected patients, after sustained period remission. Following discontinuation, cases relapse, evidence to date suggested that remission may often regained by re-treatment...
Despite the introduction of potent biologic therapies, many patients with Crohn's disease [CD] still require an ileocolonic resection [ICR] during course their disease. Furthermore, need redo ICR has not decreased over past few decades, highlighting for better strategies to prevent and treat postoperative recurrence [POR]. The first step develop such a strategy would be define standardise description POR adequate diagnostic instruments. In this article, we will describe different...
Abstract Postoperative recurrence [POR] after an ileocolonic resection with anastomosis is frequently encountered in patients Crohn’s disease. The 8th Scientific Workshop of ECCO reviewed the available evidence on pathophysiology and risk factors for POR. In this paper, we discuss published data role microbiome, mesentery, immune system genetic background. addition to investigating causative mechanisms POR, identification essential tailor preventive strategies. Potential clinical, surgical...
Background/Objectives: The management of inflammatory bowel disease (IBD) varies due to differences in healthcare systems, treatment costs, access diagnostics, and diverse clinical practices between specialists. Despite the frequent advocacy a treat-to-target (T2T) approach, there is insufficient clarity on how clinicians implement T2T real-world settings. We aim conduct large, global survey among IBD experts identify current management. Methods: A prospective, cross-sectional study was...